Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

June 22, 2022

Fotivda Now Recommended for Patients With Pretreated Kidney Cancer

Author(s):

Brielle Benyon

The National Comprehensive Cancer Network updated its guidelines to recommend Fotivda for patients with pretreated renal cell carcinoma, a type of kidney cancer.

The National Comprehensive Cancer Network (NCCN) updated its kidney cancer treatment guidelines to include Fotivda (tivozanib) in its Category 1 status — which means that the nonprofit alliance of more than 30 cancer centers strongly recommends the treatment — for patients with renal cell carcinoma who have received two or more prior therapies.

“Category 1 is the highest Category recommendation offered by NCCN, which is based on strong clinical evidence and perception of the product among the NCCN Panel Members. The NCCN guidelines are recognized and followed by both academic and community oncologists when selecting appropriate therapeutic options for their patients,” said Michael Bailey, president and CEO of AVEO, the pharmaceutical company that makes Fotivda, in a press release.

Fotivda is a tyrosine kinase inhibitor (TKI) that is taken orally, and works by inhibiting vascular endothelial growth factor receptor (VEGFR), which plays a key role in the development of cancer cells.

The NCCN based its recommendation on findings from the phase 3 TIVO-3 clinical trial, which showed that Fotivda had similar efficacy to Nexavar (sorafenib), another drug commonly used in this setting, while also presenting with fewer severe side effects.

Long-term data from TIVO-3 showed that treatment with Fotivda elicited a higher overall response rate (percentage of patients whose disease shrinks as a result of treatment) than Nexavar, at 10% and 8%, respectively.

Additionally, long-term progression-free survival(time from treatment until disease gets worse) rates were higher with Fotivda than Nexavar. At 36 months after treatment, 12.3% of patients on Fotivda did not experience disease progression, compared to 2.4% for those on Nexavar. At 48 months, progression-free survival rates were 7.6% and 0% for the Fotivda and Nexavar groups, respectively.

In 2021, the Food and Drug Administration approved Fotivda for relapsed/refractory advanced, pretreated RCC, based on earlier findings from the trial.

“This year we presented encouraging long-term, progression-free survival and overall survival follow-up data from the phase 3 TIVO-3 study. These new data demonstrate the durability of Fotivda's anti-tumor activity which has translated into an improving overall survival hazard ratio,” Bailey said.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Robotic and minimally invasive kidney cancer surgery may reduce pain, shorten recovery time and preserve kidney function, according to Dr. Armine Smith.
Robotic Kidney Cancer Surgery May Aid Recovery, Spare Kidney Function
A Kidney Cancer Advocate Shares Advice for Newly Diagnosed Patients
A Kidney Cancer Advocate Shares Advice for Newly Diagnosed Patients
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
Breaking Down Kidney Cancer Treatment Advancements and Providing Hope
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Metastatic Kidney Cancer Requires a Multidisciplinary Approach to Care
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
ctDNA Testing May Offer Patients With RCC ‘Peace of Mind’
Dr. David A. Braun, an Assistant Professor of Medicine, Medical Oncology, and a Louis Goodman and Alfred Gilman Yale Scholar, at the Yale School of Medicine, as well as a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center, in New Haven, Connecticut
How Do Molecular Factors Impact Response to Immunotherapy in Kidney Cancer?
Image of Dr. Braun.
An Expert Expands on What Drives ‘Exceptional’ Responses to RCC Treatment
Image of a man with short black hair.
Discussing Radiation as a Treatment Option for Kidney Cancer
Image of a man with short black hair.
Managing Symptoms, Controlling Disease With Radiation in Kidney Cancer
What Are Biomarkers and How Are They Used in Kidney Cancer?
What Are Biomarkers and How Are They Used in Kidney Cancer?
Related Content
Advertisement
Illustration of bladder.
May 6th 2025

The Importance of Personalized Treatment Approaches for Urologic Cancers

Ryan Scott
Dr. Armine Smith discusses the importance of personalized therapeutic approaches for the treatment of urologic cancers, such as bladder or kidney cancer.
March is Kidney Cancer Awareness Month, and voices like Sid Sadler are raising awareness: © Axel Kock - stock.adobe.com
March 27th 2025

Kidney Cancer Awareness Month Highlights Advocacy and Early Detection

Ryan Scott
March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like Sid Sadler raising awareness.
Image of kidneys.
January 28th 2025

Identifying Drivers of Exceptional Response to Immunotherapy in Metastatic RCC

Ryan Scott
In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.
Image of a doctor sitting next to a patient.
September 26th 2024

Palliative Care in Kidney Cancer More Than Just Relieving Symptoms

Ashley Chan
Patients with kidney cancer who want more support during treatment can consider palliative care, whether it’s for symptoms or discussing goals and values.
Illustration of a person's kidneys.
June 24th 2024

Expectations for Postsurgical Treatments in Kidney Cancer

Ashley Chan
For patients with kidney cancer undergoing postsurgical treatments, it’s key to understand how immunotherapy works and what side effects to look for.
Image of a patient receiving radiation therapy.
March 29th 2024

What Patients With Kidney Cancer Need to Know About Radiation Therapy

Alex Biese
An expert explains what patients need to keep in mind and what conversations they should be having with their care teams.
Related Content
Advertisement
Illustration of bladder.
May 6th 2025

The Importance of Personalized Treatment Approaches for Urologic Cancers

Ryan Scott
Dr. Armine Smith discusses the importance of personalized therapeutic approaches for the treatment of urologic cancers, such as bladder or kidney cancer.
March is Kidney Cancer Awareness Month, and voices like Sid Sadler are raising awareness: © Axel Kock - stock.adobe.com
March 27th 2025

Kidney Cancer Awareness Month Highlights Advocacy and Early Detection

Ryan Scott
March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like Sid Sadler raising awareness.
Image of kidneys.
January 28th 2025

Identifying Drivers of Exceptional Response to Immunotherapy in Metastatic RCC

Ryan Scott
In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.
Image of a doctor sitting next to a patient.
September 26th 2024

Palliative Care in Kidney Cancer More Than Just Relieving Symptoms

Ashley Chan
Patients with kidney cancer who want more support during treatment can consider palliative care, whether it’s for symptoms or discussing goals and values.
Illustration of a person's kidneys.
June 24th 2024

Expectations for Postsurgical Treatments in Kidney Cancer

Ashley Chan
For patients with kidney cancer undergoing postsurgical treatments, it’s key to understand how immunotherapy works and what side effects to look for.
Image of a patient receiving radiation therapy.
March 29th 2024

What Patients With Kidney Cancer Need to Know About Radiation Therapy

Alex Biese
An expert explains what patients need to keep in mind and what conversations they should be having with their care teams.
Advertisement
Advertisement
Advertisement
x
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.